Published in J Nucl Med on May 01, 1992
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A (2000) 1.69
Pretargeted molecular imaging and radioimmunotherapy. Theranostics (2012) 1.31
Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg (1998) 1.30
Non-invasive monitoring of BMP-2 retention and bone formation in composites for bone tissue engineering using SPECT/CT and scintillation probes. J Control Release (2008) 0.98
99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection. Br J Cancer (1998) 0.84
99mTc-labeled HAb18 McAb Fab fragment for radioimmunoimaging in nude mice bearing human hepatocellular carcinoma. World J Gastroenterol (1998) 0.81
Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg (1997) 0.77
Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance. Mol Pharm (2017) 0.75
Avoiding hepatic metastasis naturally: Lessons from the cotton top tamarin (Saguinus oedipus). World J Gastroenterol (2016) 0.75
Radiometric detection of the metabolic activity of Mycobacterium tuberculosis. J Nucl Med (1975) 5.30
Automated detection of Haemophilus influenzae. Appl Microbiol (1973) 3.16
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer (1997) 2.81
Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res (1998) 2.55
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res (1998) 2.43
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst (1991) 2.19
Imaging transgene expression with radionuclide imaging technologies. Neoplasia (2000) 2.03
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol (2002) 1.96
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab (1999) 1.90
Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med (2000) 1.74
Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys (2004) 1.74
Quantitative imaging of iodine-124 with PET. J Nucl Med (1996) 1.69
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid (2000) 1.59
Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab (2000) 1.59
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol (1998) 1.56
Phase and amplitude binning for 4D-CT imaging. Phys Med Biol (2007) 1.52
Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning. J Nucl Med (1966) 1.49
FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med (2001) 1.49
Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys (2002) 1.48
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol (1988) 1.41
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol (1994) 1.41
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg (1999) 1.41
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med (1990) 1.41
Triumph over mischance: a role for nuclear medicine in gene therapy. J Nucl Med (1997) 1.41
Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology (2001) 1.40
Quantitative bone metastases analysis based on image segmentation. J Nucl Med (1997) 1.36
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol (1993) 1.35
Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys (2004) 1.35
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35
3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol (1998) 1.35
Dimensions of the normal adult spleen scan and prediction of spleen weight. J Nucl Med (1971) 1.33
Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg (1985) 1.27
Midazolam changes cerebral blood flow in discrete brain regions: an H2(15)O positron emission tomography study. Anesthesiology (1997) 1.25
A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia (1999) 1.25
Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med (1983) 1.24
Effects of obstetrician gender on communication and patient satisfaction. Obstet Gynecol (1999) 1.23
Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab (2013) 1.21
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1996) 1.21
The radionuclide ejection fraction: a comparison of three radionuclide techniques with contrast angiography. J Nucl Med (1977) 1.18
Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid (2001) 1.17
The pharmacology of monoclonal antibodies. Ann N Y Acad Sci (1987) 1.15
Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J Nucl Med (1985) 1.14
Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med (1996) 1.13
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res (2001) 1.12
Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia (2001) 1.11
Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys (1997) 1.10
Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol (2001) 1.10
Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation (1987) 1.09
Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol (2006) 1.09
An unusual cause of partial ETT obstruction. Anesthesiology (1998) 1.09
Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat Med (2001) 1.08
Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med (1988) 1.08
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res (1998) 1.07
Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med (2000) 1.07
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1994) 1.06
Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res (1994) 1.05
Visualization of the placenta by radioisotope photoscanning using technetium-99m-labeled albumin. Am J Obstet Gynecol (1965) 1.04
Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol (1996) 1.03
Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med (2001) 1.02
Acquired immunodeficiency syndrome: Ga-67 citrate imaging. Radiology (1987) 0.99
Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys (1991) 0.99
N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol (2001) 0.98
Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Int J Rad Appl Instrum B (1989) 0.97
An automated system for measurement of leukocyte metabolism. J Nucl Med (1974) 0.96
Jod-Basedow syndrome following oral iodine and radioiodinated-antibody administration. J Nucl Med (1997) 0.96
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant (2003) 0.95
Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med (1997) 0.95
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid (2001) 0.95
Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Cancer Res (1998) 0.94
Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med (1993) 0.94
Lymphoscintigraphy and sentinel node localization in breast cancer patients: a comparison between 1-day and 2-day protocols. J Nucl Med (2001) 0.94
Radiometric measurement of differential metabolism of fatty acid by mycobacteria. Int J Lepr Other Mycobact Dis (1982) 0.93
Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer (1987) 0.93
Prenatal genetic testing: content of discussions between obstetric providers and pregnant women. Obstet Gynecol (1998) 0.93
Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. J Nucl Med (1999) 0.93
Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med (2001) 0.93
Targeting cancer with radiolabeled antibodies. Immunol Today (1995) 0.93
Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med (1991) 0.92
Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. Cancer Res (1987) 0.92
Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys (2003) 0.92
Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab (2011) 0.92
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol (2011) 0.91
Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med (1996) 0.91
Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst (1980) 0.90
Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med (1994) 0.90
Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res (1984) 0.90
Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res (1995) 0.90
Effect of barbiturate coma on glucose utilization in normal brain versus gliomas. Positron emission tomography studies. J Neurosurg (1987) 0.90
PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels. J Nucl Med (2001) 0.90
Brain glucose metabolism in noninsulin-dependent diabetes mellitus: a study in Pima Indians using positron emission tomography during hyperinsulinemia with euglycemic glucose clamp. J Clin Endocrinol Metab (1990) 0.89
An iterative technique to segment PET lesions using a Monte Carlo based mathematical model. Med Phys (2009) 0.89
Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gynecol Oncol (1993) 0.89
Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med (1993) 0.89
Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res (1999) 0.89